Found 4 hits in this display Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Nuclear receptor subfamily 2 group C member 2
(Homo sapiens (Human)) | BDBM375281
(US10597387, Compound (I-4) | US9908872, Compound (...)Show SMILES CN1CCN(CC1)c1cc(NC(=O)c2ccc(C)c(NC(=O)c3cncc(c3)-c3cccs3)c2)cc(c1)C(F)(F)F Show InChI InChI=1S/C30H28F3N5O2S/c1-19-5-6-20(13-26(19)36-29(40)22-12-21(17-34-18-22)27-4-3-11-41-27)28(39)35-24-14-23(30(31,32)33)15-25(16-24)38-9-7-37(2)8-10-38/h3-6,11-18H,7-10H2,1-2H3,(H,35,39)(H,36,40) | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 22.8 | n/a | n/a | n/a | n/a | n/a | n/a |
The Scripps Research Institute
| Assay Description
The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... |
J Med Chem 50: 3359-68 (2007)
BindingDB Entry DOI: 10.7270/Q2668GH3 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase HCK
(Homo sapiens (Human)) | BDBM375281
(US10597387, Compound (I-4) | US9908872, Compound (...)Show SMILES CN1CCN(CC1)c1cc(NC(=O)c2ccc(C)c(NC(=O)c3cncc(c3)-c3cccs3)c2)cc(c1)C(F)(F)F Show InChI InChI=1S/C30H28F3N5O2S/c1-19-5-6-20(13-26(19)36-29(40)22-12-21(17-34-18-22)27-4-3-11-41-27)28(39)35-24-14-23(30(31,32)33)15-25(16-24)38-9-7-37(2)8-10-38/h3-6,11-18H,7-10H2,1-2H3,(H,35,39)(H,36,40) | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 22.8 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc.
US Patent
| Assay Description
The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... |
US Patent US10597387 (2020)
BindingDB Entry DOI: 10.7270/Q2ZC85X9 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM375281
(US10597387, Compound (I-4) | US9908872, Compound (...)Show SMILES CN1CCN(CC1)c1cc(NC(=O)c2ccc(C)c(NC(=O)c3cncc(c3)-c3cccs3)c2)cc(c1)C(F)(F)F Show InChI InChI=1S/C30H28F3N5O2S/c1-19-5-6-20(13-26(19)36-29(40)22-12-21(17-34-18-22)27-4-3-11-41-27)28(39)35-24-14-23(30(31,32)33)15-25(16-24)38-9-7-37(2)8-10-38/h3-6,11-18H,7-10H2,1-2H3,(H,35,39)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 459 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc.
US Patent
| Assay Description
The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... |
US Patent US10597387 (2020)
BindingDB Entry DOI: 10.7270/Q2ZC85X9 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM375281
(US10597387, Compound (I-4) | US9908872, Compound (...)Show SMILES CN1CCN(CC1)c1cc(NC(=O)c2ccc(C)c(NC(=O)c3cncc(c3)-c3cccs3)c2)cc(c1)C(F)(F)F Show InChI InChI=1S/C30H28F3N5O2S/c1-19-5-6-20(13-26(19)36-29(40)22-12-21(17-34-18-22)27-4-3-11-41-27)28(39)35-24-14-23(30(31,32)33)15-25(16-24)38-9-7-37(2)8-10-38/h3-6,11-18H,7-10H2,1-2H3,(H,35,39)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 459 | n/a | n/a | n/a | n/a | n/a | n/a |
The Scripps Research Institute
| Assay Description
The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... |
J Med Chem 50: 3359-68 (2007)
BindingDB Entry DOI: 10.7270/Q2668GH3 |
More data for this
Ligand-Target Pair | |